Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel ...

Related Keywords

Canada ,Israel ,United Kingdom ,United States ,America ,Gilad Mamlok ,Company Annual Report On Form ,Gel Technologies Ltd ,Zinsight Technology ,Drug Administration ,Nasdaq ,European Medical Association ,Pellepharm Inc ,Exchange Commission ,Searchlight Pharma Inc ,Gorlin Syndrome ,Gel Technologies ,Orphan Drug ,North America ,Searchlight Pharma ,Markets Insight ,Chief Executive Officer ,Year Ended December ,Private Securities Litigation Reform Act ,Annual Report ,Gel Contact ,Sol Gel Technologies ,